BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Stock Information for Tempest Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tempest Therapeutics Inc.

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
BioXcel Therapeutics Announces $14 Million Registered Direct Offering
BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia
BioXcel Therapeutics Announces Reverse Stock Split
BioXcel Therapeutics Provides Clinical and Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.